OSTEOP
MCID: OST002
MIFTS: 81

Osteoporosis (OSTEOP)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Osteoporosis

MalaCards integrated aliases for Osteoporosis:

Name: Osteoporosis 57 11 75 73 28 53 5 41 43 14 36 63 38 16 71 33
Postmenopausal Osteoporosis 73 28 5 16 31 33
Osteoporosis, Postmenopausal 57 71
Bone Mineral Density Variation Qtl, Osteoporosis 57
Bone Mineral Density, Quantitative Trait Locus 38
Bone Mineral Density Quantitative Trait Locus 57
Osteoporosis, Postmenopausal, Susceptibility 57
Osteoporosis, Susceptibility to 57
Osteoporosis Postmenopausal 53
Osteoporosis, Involutional 57
Involutional Osteoporosis 73
Idiopathic Osteoporosis 33
Osteoporosis, Senile 71
Bone Rarefaction Nos 33
Senile Osteoporosis 73
Type 1 Osteoporosis 33
Osteop 73
Bmnd 57

Characteristics:


Inheritance:

Autosomal dominant 57

Classifications:



External Ids:

Disease Ontology 11 DOID:11476
OMIM® 57 166710
ICD9CM 34 733.0
MeSH 43 D010024
NCIt 49 C3298
SNOMED-CT 68 156825006
SNOMED-CT via HPO 69 64859006
UMLS 71 C0029456 C0029458 C0029459

Summaries for Osteoporosis

MedlinePlus: 41 Osteoporosis is a disease that thins and weakens the bones. Your bones become fragile and fracture (break) easily, especially the bones in the hip, spine, and wrist. In the United States, millions of people either already have osteoporosis or are at high risk due to low bone mass. Anyone can develop osteoporosis, but it is more common in older women. Risk factors include: Getting older Being small and thin Having a family history of osteoporosis Taking certain medicines Being a white or Asian woman Having low bone density Osteoporosis is a silent disease. You might not know you have it until you break a bone. A bone mineral density test is the best way to check your bone health. To keep bones strong, eat a diet rich in calcium and vitamin D, exercise, and do not smoke. If needed, medicines can also help. It is also important to try to avoid falling down. Falls are the number one cause of fractures in older adults. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary: Osteoporosis, also known as postmenopausal osteoporosis, is related to osteoporosis, juvenile and bone mineral density quantitative trait locus 15, and has symptoms including angina pectoris, back pain and muscle cramp. An important gene associated with Osteoporosis is COL1A1 (Collagen Type I Alpha 1 Chain), and among its related pathways/superpathways are Breast cancer pathway and Vitamin D receptor pathway. The drugs Clobetasol and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include Bone, and related phenotypes are osteoporosis and homeostasis/metabolism

PubMed Health : 63 Osteoporosis: Having weak bones that easily break is a sign of osteoporosis. It is normal for your bones to become less dense as you grow older, but osteoporosis speeds up this process. This condition can particularly lead to problems in older age because broken bones do not heal as easily in older people as they do in young people, and the consequences are more serious. In general, osteoporosis is more common in women, and they often develop it at a younger age. Getting older does not mean that you will automatically develop osteoporosis, but the risk does increase with age. People over the age of 70 are more likely to have low bone density. Plus, the risk of falling increases in old age, which then also makes fractures more likely. But there are several things you can do to protect and strengthen your bones – even if you are already older.

UniProtKB/Swiss-Prot: 73 A systemic skeletal disorder characterized by decreased bone mass and deterioration of bone microarchitecture without alteration in the composition of bone. The result is fragile bones and an increased risk of fractures, even after minimal trauma. Osteoporosis is a chronic condition of multifactorial etiology and is usually clinically silent until a fracture occurs.

Disease Ontology: 11 A bone resorption disease characterized by decreased density of normally mineralized bone which results in the thinning of bone tissue and decreased mechanical strength.

Wikipedia: 75 Osteoporosis is a systemic skeletal disorder characterized by low bone mass, micro-architectural... more...

More information from OMIM: 166710

Related Diseases for Osteoporosis

Diseases in the Osteoporosis family:

Osteoporosis, Juvenile Juvenile Primary Osteoporosis
Lrp5-Related Primary Osteoporosis

Diseases related to Osteoporosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1440)
# Related Disease Score Top Affiliating Genes
1 osteoporosis, juvenile 34.0 WNT1 TNFSF11 PLS3 LRP5 IFITM5 COL1A2
2 bone mineral density quantitative trait locus 15 33.8 PDLIM4 CALCR
3 osteoporosis-pseudoglioma syndrome 33.7 WNT1 TNFSF11 LRP5
4 glucocorticoid-induced osteoporosis 33.6 TNFSF11 LRP5 ESR1 CALCA BGLAP
5 bone disease 33.4 TNFSF11 TNFRSF11B TNFRSF11A LRP5 ESR1 DANCR
6 bone resorption disease 33.2 TNFSF11 LRP5 ESR1 COL1A2 COL1A1 CALCA
7 hyperparathyroidism 32.8 TNFSF11 TNFRSF11B CALCA BGLAP
8 osteopetrosis 32.7 TNFSF11 TNFRSF11B TNFRSF11A LRP5 CALCR CALCA
9 cleidocranial dysplasia 32.4 TNFSF11 COL1A1 BGLAP
10 osteonecrosis 32.4 TNFRSF11B LRP5 ESR1 BGLAP
11 brittle bone disorder 32.3 WNT1 TNFSF11 TNFRSF11B TNFRSF11A PLS3 LRP5
12 mammary paget's disease 32.2 TNFSF11 TNFRSF11B TNFRSF11A ESR1 CALCA BGLAP
13 osteomalacia 32.1 TNFSF11 CALCA BGLAP
14 primary hyperparathyroidism 32.0 TNFSF11 COL1A1 CALCA BGLAP
15 chronic kidney disease 32.0 TNFSF11 TNFRSF11B ESR1 CALCA BGLAP
16 sclerosteosis 31.9 WNT1 TNFSF11 LRP5 COL1A1 BGLAP
17 secondary hyperparathyroidism 31.9 TNFRSF11B CALCA BGLAP
18 scoliosis 31.9 TNFSF11 TNFRSF11B TNFRSF11A ESR1 COL1A2 COL1A1
19 spondyloarthropathy 1 31.8 TNFSF11 TNFRSF11B BGLAP
20 osteogenic sarcoma 31.8 TNFSF11 TNFRSF11B TNFRSF11A ESR1 DANCR BGLAP
21 paget's disease of bone 31.7 TNFSF11 TNFRSF11B TNFRSF11A CALCA BGLAP
22 connective tissue disease 31.7 TNFSF11 ESR1 COL1A2 COL1A1 CALCA BGLAP
23 beta-thalassemia 31.7 TNFSF11 TNFRSF11B ESR1 BGLAP
24 type 1 diabetes mellitus 31.7 TNFSF11 TNFRSF11B LRP5 CALCA BGLAP
25 renal osteodystrophy 31.6 TNFSF11 TNFRSF11B CALCA BGLAP
26 arthropathy 31.6 TNFSF11 TNFRSF11B TNFRSF11A
27 sclerosteosis 1 31.5 TNFRSF11B BGLAP
28 endosteal hyperostosis, autosomal dominant 31.5 TNFSF11 TNFRSF11B LRP5 COL1A2 COL1A1
29 van buchem disease 31.4 WNT1 TNFSF11 LRP5 COL1A1 BGLAP
30 osteochondrodysplasia 31.4 WNT1 TNFSF11 PLS3 LRP5 IFITM5 COL1A2
31 hyperostosis 31.3 TNFRSF11B LRP5 COL1A1
32 osteomyelitis 31.3 TNFSF11 TNFRSF11A CALCA
33 spinal stenosis 31.2 COL1A2 COL1A1 CALCA
34 fibrous dysplasia 31.2 TNFSF11 TNFRSF11A CALCA BGLAP
35 ankylosis 31.1 TNFSF11 TNFRSF11B BGLAP
36 osteogenesis imperfecta, type i 31.1 PLS3 IFITM5 COL1A2 COL1A1 BGLAP
37 periodontitis, chronic 31.1 TNFSF11 TNFRSF11B
38 scleroderma, familial progressive 31.1 COL1A2 COL1A1
39 marfan syndrome 31.0 ESR1 COL1A2 COL1A1
40 otosclerosis 31.0 TNFSF11 TNFRSF11B COL1A2 COL1A1 CALCA
41 ehlers-danlos syndrome, arthrochalasia type, 1 30.9 COL1A2 COL1A1
42 aortic valve disease 2 30.8 TNFSF11 TNFRSF11B BGLAP
43 osteogenesis imperfecta, type vi 30.8 TNFSF11 IFITM5 COL1A2 COL1A1
44 osteitis fibrosa 30.7 CALCA BGLAP
45 osteogenesis imperfecta, type xv 30.6 WNT1 PLS3 LRP5
46 dental fluorosis 30.5 COL1A2 BGLAP
47 osteogenesis imperfecta, type iii 30.5 WNT1 IFITM5 COL1A2 COL1A1 BGLAP
48 tooth agenesis 30.4 WNT1 LRP5 COL1A2 COL1A1
49 camurati-engelmann disease 30.4 TNFRSF11B LRP5 BGLAP
50 osteogenesis imperfecta, type v 30.4 IFITM5 COL1A2 COL1A1

Comorbidity relations with Osteoporosis via Phenotypic Disease Network (PDN): (show top 50) (show all 85)


Active Peptic Ulcer Disease Acute Cor Pulmonale
Acute Cystitis Alzheimer Disease, Familial, 1
Anxiety Aortic Atherosclerosis
Aortic Valve Disease 1 Asthma
Benign Essential Hypertension Bronchiectasis
Bronchitis Bronchopneumonia
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Chronic Pulmonary Heart Disease
Chylomicron Retention Disease Conjunctivitis
Conn's Syndrome Cystitis
Decubitus Ulcer Deficiency Anemia
Dermatomycosis Dyskinesia of Esophagus
Dysthymic Disorder Esophagitis
Femoral Vein Thrombophlebitis Gastroesophageal Reflux
Generalized Anxiety Disorder Generalized Atherosclerosis
Heart Disease Hyperparathyroidism
Hypertension, Essential Hyperuricemia, Pulmonary Hypertension, Renal Failure, and Alkalosis Syndrome
Hypothyroidism Idiopathic Interstitial Pneumonia
Inflammatory Bowel Disease 1 Intervertebral Disc Disease
Intestinal Obstruction Iron Deficiency Anemia
Irritable Bowel Syndrome Macular Degeneration, Age-Related, 1
Major Depressive Disorder Marasmus
Monoclonal Paraproteinemia Neurogenic Bladder
Nutritional Deficiency Disease Opiate Dependence
Oral Candidiasis Osteoarthritis

Graphical network of the top 20 diseases related to Osteoporosis:



Diseases related to Osteoporosis

Symptoms & Phenotypes for Osteoporosis

Human phenotypes related to Osteoporosis:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 osteoporosis 30 HP:0000939

Symptoms via clinical synopsis from OMIM®:

57 (Updated 24-Oct-2022)
Skel:
postmenopausal osteoporosis

Clinical features from OMIM®:

166710 (Updated 24-Oct-2022)

UMLS symptoms related to Osteoporosis:


angina pectoris; back pain; muscle cramp; pelvic pain; sciatica; tremor; equilibration disorder

MGI Mouse Phenotypes related to Osteoporosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 BGLAP CALCA CALCR COL1A1 COL1A2 ESR1
2 limbs/digits/tail MP:0005371 10.11 CALCR COL1A1 COL1A2 ESR1 IFITM5 LRP5
3 behavior/neurological MP:0005386 9.93 CALCA CALCR COL1A1 COL1A2 ESR1 LRP5
4 craniofacial MP:0005382 9.8 COL1A1 IFITM5 LRP5 TNFRSF11A TNFRSF11B TNFSF11
5 skeleton MP:0005390 9.8 BGLAP CALCA CALCR COL1A1 COL1A2 ESR1
6 hematopoietic system MP:0005397 9.4 BGLAP CALCR COL1A1 COL1A2 ESR1 IFITM5

Drugs & Therapeutics for Osteoporosis

PubMed Health treatment related to Osteoporosis: 63

Even if someone already has osteoporosis , it is important for them to do regular exercise and get enough calcium and vitamin D . In Germany, statutory health insurances cover the cost of calcium or vitamin D supplements if a doctor has prescribed them. Osteoporosis can be treated with several drugs designed to slow bone loss and increase the production of new bone tissue . These include bisphosphonates and some hormonal or hormone -like medications. These kinds of drugs can have different types of side effects, though, and may not be suitable for everyone. They are only considered if someone has already broken a bone, or if their risk of bone fractures is high – for example, if their bone density is very low or if they have a combination of different risk factors, like low body weight, old age and a higher risk of falling . Hormone products, like those used to treat menopause symptoms , can also lower the risk of osteoporosis -related bone fractures when taken over the long term. But long-term hormone therapy during or after menopause increases the risk of cardiovascular diseases and breast cancer . For this reason it is only rarely recommended as treatment for osteoporosis. The pros and cons of this treatment should be carefully weighed.

Drugs for Osteoporosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 385)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 2791 5311051 32798
2
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
3
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
4
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
5
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
6
Linagliptin Approved Phase 4 668270-12-0 57389748 10096344
7
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
8
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
9
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
10
Bazedoxifene Approved, Investigational Phase 4 198481-32-2 154257
11 Strontium ranelate Approved, Withdrawn Phase 4 135459-87-9
12
Medroxyprogesterone acetate Approved, Investigational Phase 4 520-85-4, 71-58-9 10631 6279
13
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
14
Demeclocycline Approved Phase 4 127-33-3 5311063
15
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
16
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
17
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
18
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
19
Lactitol Approved, Investigational Phase 4 585-86-4, 585-88-6 157355 493591
20
Tibolone Approved, Investigational Phase 4 5630-53-5 5470 444008
21
Acetaminophen Approved Phase 4 103-90-2 1983
22
Atorvastatin Approved Phase 4 134523-00-5 60823
23
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
24
Gliclazide Approved Phase 4 21187-98-4 3475
25
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
26
Abaloparatide Approved, Investigational Phase 4 247062-33-5
27
Cinacalcet Approved Phase 4 226256-56-0 156419
28
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
29
Dolutegravir Approved Phase 4 1051375-16-6 57414794 54726191
30
Racivir Approved, Investigational Phase 4 143491-57-0, 143491-54-7 60877
31
Zoledronic acid Approved Phase 4 118072-93-8 68740
32
Pravastatin Approved Phase 4 81093-37-0 54687
33
Alendronic acid Approved Phase 4 121268-17-5, 66376-36-1 2088
34
Denosumab Approved Phase 4 615258-40-7
35
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850 155817470
36
Raloxifene Approved, Investigational Phase 4 82640-04-8, 84449-90-1 5035
37
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453
38
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
39
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
40
Menatetrenone Investigational Phase 4 56973-41-2, 863-61-6 5282367
41
Tenofovir Experimental, Investigational Phase 4 147127-20-6, 202138-50-9 464205 6398764
42 Omega 3 Fatty Acid Phase 4
43 Hydrocortisone 17-butyrate 21-propionate Phase 4
44 calcium channel blockers Phase 4
45 Vitamin K 2 Phase 4
46 Anesthetics Phase 4
47 Calcium Supplement Phase 4
48 Expectorants Phase 4
49 diuretics Phase 4
50 Adjuvants, Immunologic Phase 4

Interventional clinical trials:

(show top 50) (show all 1410)
# Name Status NCT ID Phase Drugs
1 Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
2 Generic Zoledronic Acid Versus Original Zoledronic Acid: A Multicenter, Randomized, Open, Paralled-controlled Clinical Postmenopausal Osteoporotic Women Efficacy and Safety Research. Unknown status NCT03158246 Phase 4 Generic Zoledronic Acid;Original Zoledronic Acid
3 Effect of Mechanical Loading With PTH on Cortical Bone Unknown status NCT03232476 Phase 4
4 The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab Unknown status NCT02130973 Phase 4 Standard Clinical Practice Regimen;Experimental Cyclic Regimen
5 Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
6 The Assessment of Osteoporosis Treatment in Post-menopausal Women Unknown status NCT03006003 Phase 4 Raloxifene;Alendronate
7 The Efficacy of Denosumab to Reduce Osteoporosis After Spinal Cord Injury Unknown status NCT01983475 Phase 4 Denosumab;Placebo (identical Denosumab volume of normal saline)
8 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
9 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
10 Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers Unknown status NCT02587975 Phase 4 Evogliptin
11 Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid Unknown status NCT03926377 Phase 4
12 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
13 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
14 Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
15 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
16 Pilot Study: Does Preventive Adjacent Level Cement Augmentation Positively Affect Reoperation Rates After Osteoporotic Vertebral Compression Fractures? Unknown status NCT02489825 Phase 4
17 A Multi Centre, Randomised, Open Label, Cross-over Study to Evaluate the Percentage of False Negative Osteoporosis Diagnosis's Using the Standard Case-finding Procedure as Described by the Dutch Institute for Healthcare (CBO) and to Determine the Preference of Adult Osteoporosis Patients Between Once Monthly Dosing of Ibandronate (150 mg) and Once Weekly Dosing of Alendronate (70 mg) Completed NCT00327990 Phase 4 Ibandronate;Alendronate
18 Comparison of Raloxifene and Strontium Ranelate on Compliance and Efficacy in Women With Postmenopausal Osteoporosis Completed NCT01544894 Phase 4 Raloxifene;Strontium ranelate
19 ZEST II for Osteoporotic Fracture Prevention Completed NCT02589600 Phase 4 Zoledronic acid
20 A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study Completed NCT02598440 Phase 4 Alendronate;Ibandronate
21 A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women Completed NCT00729651 Phase 4 alendronate sodium (+) cholecalciferol;Comparator: Alendronate sodium (Fosamax)
22 A Study of Prevention and Treatment of Postmenopausal Osteoporosis in Chinese Women Completed NCT00860964 Phase 4 Placebo;estradiol valerate
23 Multi-centre, Randomized, Open Label Trial to Evaluate the Effects of Switching to Bazedoxifene in Comparison With Switching to Calcium and Vitamin D in Postmenopausal Women Previously Treated With Bisphosphonates Completed NCT02090400 Phase 4 Bazedoxifene;Calcium/Vit D
24 Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures Completed NCT01709110 Phase 4 Teriparatide;Risedronate;Placebo;Calcium;Vitamin D
25 An Open-Label, Multi-Center Study to Determine Level of Adherence to Monthly Oral or Every Three Month Intravenous Ibandronate Treatment in Post-Menopausal Women With Osteoporosis or Osteopenia, Who Are GI Intolerant of Daily or Weekly Alendronate or Risendronate Completed NCT02598453 Phase 4 Ibandronate
26 Prevention of Osteoporosis in Breast Cancer Survivors Completed NCT00567606 Phase 4
27 Multicenter and Prospective Study to Determine the Satisfaction With Actonel (Risedronate Sodium) 35mg Once a Week Using Biochemical Markers of Bone as a Control, in Postmenopausal Women With Osteoporosis Completed NCT00632216 Phase 4 Risedronate Sodium
28 A Randomized, Double-blind Study to Evaluate the Effect of Once Monthly Bonviva on Lumbar Bone Mineral Density in the Prevention of Glucocorticoid-induced Osteoporosis in Post-menopausal Women Completed NCT00545051 Phase 4 Placebo;ibandronate
29 A Randomized, Double-blind, Placebo-controlled Study to Determine Time to Onset of Suppression of the Bone Resorption Marker sCTX With Once Monthly Ibandronate in the Treatment of Postmenopausal Osteoporosis Completed NCT00303485 Phase 4 Placebo;Vitamin D and calcium supplementation;ibandronate [Bonviva/Boniva]
30 Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women With Osteoporosis Completed NCT00239629 Phase 4 Teriparatide;Strontium ranelate
31 Denosumab and Teriparatide Study (DATA-HD and DATA-EX) Completed NCT02176382 Phase 4 denosumab;teriparatide;Zoledronic acid
32 A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Phase IV Study in Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Actonel(Rosedronate) is Administered 35mg Once a Week or 5mg Completed NCT00549965 Phase 4 Risedronate Sodium
33 An Open-label, Clinical Observation Extension Study to Assess Continuing Safety and Adherence in Patients With Postmenopausal Osteoporosis Receiving Monthly Oral Bonviva Completed NCT00545090 Phase 4 ibandronate [Bonviva/Boniva]
34 A Randomised, Open Label Study to Investigate the Impact of Bone Marker Feedback at 2 Months on Adherence to Monthly Oral Bonviva (Ibandronate) in Women With Post-menopausal Osteoporosis. Completed NCT00545909 Phase 4 ibandronate [Bonviva/Boniva]
35 Comparison of a 2-Year Therapy of Teriparatide Alone and Its Sequential Use for 1 Year, With or Without Raloxifene HCl, in the Treatment of Severe Postmenopausal Osteoporosis Completed NCT00191425 Phase 4 Teriparatide;Raloxifene
36 Open-Label Study to Determine How Prior Therapy With Alendronate or Risedronate in Postmenopausal Women With Osteoporosis Influences the Clinical Effectiveness of Teriparatide Completed NCT00130403 Phase 4 risedronate sodium
37 Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy Completed NCT00927186 Phase 4 Teriparatide;Zoledronic Acid
38 A Randomized Open-Label Study to Investigate the Impact of Bone Marker Feedback at 3 Months on Adherence to Monthly Oral Bonviva in Women With Post-Menopausal Osteoporosis Supported by a Patient Relationship Program Completed NCT00545363 Phase 4 Ibandronate
39 Randomized, Open-label, Multi-center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once Monthly Ibandronate and Once Weekly Risedronate. A Six Month, Two-sequence and Two-period Crossover Study. Completed NCT00377234 Phase 4 Risedronate;ibandronate [Bonviva/Boniva]
40 Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis Completed NCT00035256 Phase 4 teriparatide;raloxifene HCl;placebo
41 Effect of Periodontal Therapy and Bisphosphonates on Gingival Crevicular Fluid Levels of Nuclear Factor- κb Ligand (RANKL) and Osteoprotegerin in Postmenopausal Osteoporosis: Results of a 12-Month Study Completed NCT02808988 Phase 4
42 Open Label, Parallel Group, Multicenter Study of Two Intravenous (IV) Ibandronate Dose Regimens (2 mg Every 2 Months and 3 mg Every 3 Months) in Women With Postmenopausal Osteoporosis Who Completed Trial BM16550 Completed NCT00551174 Phase 4 ibandronate [Bonviva/Boniva]
43 Bone Marker Changes In One Month Treatment With TERIPARATIDE (LY333334) Injections (rDNA Origin) in Men and Postmenopausal Women With Severe Osteoporosis Completed NCT00532545 Phase 4 Teriparatide
44 An Open-label, Multi-centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-monthly Ibandronate and the Once-weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-month, Two-sequence, and Two Period Crossover Study Completed NCT00405392 Phase 4 Ibandronate (SB743830HD)
45 A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 35-mg Risedronate Administered Once a Week in the Prevention of Osteoporosis in Postmenopausal Women Completed NCT00402441 Phase 4 Risedronate (HMR4003)
46 Effects of Teriparatide in Postmenopausal Women With Osteoporosis Previously Treated With Alendronate or Raloxifene Completed NCT00079924 Phase 4 teriparatide;aldrenodate;raloxifene
47 A Randomized, Open-label Study to Investigate the Impact of Bone Marker Feedback on Persistence to Once Monthly Oral Bonviva (Ibandronate) Treatment for Post-menopausal Osteoporosis. Completed NCT00545480 Phase 4 ibandronate [Bonviva/Boniva]
48 Long-Term Effects of Raloxifene Treatment on Bone Quality: A Cross-Sectional Study of Postmenopausal Women With Osteoporosis Previously Enrolled in the Continuing Outcomes Relevant to Evista Study Completed NCT00532428 Phase 4 Raloxifene;Placebo
49 A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Study pn Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Risedronate Sodium (Actonel) in Administered 35mg Once a Week or 5mg Once Daily Completed NCT00453492 Phase 4 risedronate sodium
50 Randomized Double-Blind Placebo-Controlled and Parallel Group Study to Evaluate the Impact of One Year Therapy With Monthly Oral Ibandronate 150 mg on Structural Properties of Bone in Postmenopausal Osteoporosis Without Vertebral Fractures Completed NCT00271713 Phase 4 ibandronate, calcium and vitamin D;placebo,calcium and vitamin D

Search NIH Clinical Center for Osteoporosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alendronate
Calcitonin
calcium acetate
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium Citrate
calcium glubionate
Calcium gluceptate
Calcium Gluconate
CALCIUM GLUCONATE PWDR
Calcium Glycerophosphate
calcium lactate
CALCIUM LEVULINATE
Calcium Pantothenate
calcium phosphate
Cholecalciferol
Fluorides
Medium chain triglycerides
MEDRONATE DISODIUM
pamidronate
Pamidronate Disodium
Raloxifene
Raloxifene Hydrochloride
Risedronate
risedronate sodium
salmon calcitonin
SODIUM FLUORIDE PWDR
Teriparatide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Osteoporosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Osteoporosis:
PREOB, autologous osteoblasts for bone disorders

Cochrane evidence based reviews: osteoporosis

Genetic Tests for Osteoporosis

Genetic tests related to Osteoporosis:

# Genetic test Affiliating Genes
1 Postmenopausal Osteoporosis 28
2 Osteoporosis 28 CALCR COL1A1 COL1A2 LRP5 PDLIM4

Anatomical Context for Osteoporosis

Organs/tissues related to Osteoporosis:

MalaCards : Bone, Bone Marrow, Spinal Cord, Breast, Prostate, Skin, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Osteoporosis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Mononucleated Osteoclasts Affected by disease
2 Bone Bone Marrow Multinucleated Osteoclasts Affected by disease
3 Blood Hematopoietic Bone Marrow Osteoclast Precursor Cells Affected by disease

Publications for Osteoporosis

Articles related to Osteoporosis:

(show top 50) (show all 32770)
# Title Authors PMID Year
1
Promoter and intron 1 polymorphisms of COL1A1 interact to regulate transcription and susceptibility to osteoporosis. 53 62 57
19429913 2009
2
Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women. 53 62 57
10942433 2000
3
Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene. 53 62 57
8841196 1996
4
Genetics of osteoporosis. 62 57
16762578 2006
5
Association of oestrogen receptor alpha gene polymorphisms with postmenopausal bone loss, bone mass, and quantitative ultrasound properties of bone. 53 57
15744038 2005
6
An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. 53 57
14671165 2003
7
Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. 62 57
14602752 2003
8
Genetic control of susceptibility to osteoporosis. 62 57
12050200 2002
9
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. 62 57
11889149 2002
10
Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. 62 57
11701687 2001
11
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. 62 57
11344179 2001
12
The genetics of osteoporosis: 'complexities and difficulties'. 62 57
10782923 2000
13
The genetic trail of osteoporosis. 62 57
9535673 1998
14
Reduced femoral neck bone density in the daughters of women with hip fractures: the role of low peak bone density in the pathogenesis of osteoporosis. 62 57
8053404 1994
15
Mutation in a gene for type I procollagen (COL1A2) in a woman with postmenopausal osteoporosis: evidence for phenotypic and genotypic overlap with mild osteogenesis imperfecta. 62 5
2052622 1991
16
Reduced bone mass in daughters of women with osteoporosis. 62 57
2915666 1989
17
Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study. 62 41
35977548 2022
18
Development and validation of a machine learning-derived radiomics model for diagnosis of osteoporosis and osteopenia using quantitative computed tomography. 62 41
35941568 2022
19
Whole-genome sequencing of patients with rare diseases in a national health system. 5
32581362 2020
20
Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture. 57
26367794 2015
21
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. 57
22504420 2012
22
Multiple genetic loci for bone mineral density and fractures. 57
18445777 2008
23
Integrin beta3 Leu33Pro polymorphism and risk of hip fracture: 25 years follow-up of 9233 adults from the general population. 57
17264806 2007
24
Interspecies synteny mapping identifies a quantitative trait locus for bone mineral density on human chromosome Xp22. 57
16183656 2005
25
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. 57
15908955 2005
26
The effect of calcium supplementation on bone density in premenarcheal females: a co-twin approach. 57
15472185 2004
27
Interaction between vitamin D receptor genotype and estrogen receptor alpha genotype influences vertebral fracture risk. 57
12915669 2003
28
Association of genetic variation of the RIL gene, encoding a PDZ-LIM domain protein and localized in 5q31.1, with low bone mineral density in adult Japanese women. 57
12908099 2003
29
Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. 57
11061497 2000
30
Vitamin D supplementation in postmenopausal black women. 57
10566638 1999
31
Relation of alleles of the collagen type Ialpha1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women. 57
9535665 1998
32
Substitution of glycine-661 by serine in the alpha1(I) and alpha2(I) chains of type I collagen results in different clinical and biochemical phenotypes. 5
8786074 1996
33
Partial isodisomy for maternal chromosome 7 and short stature in an individual with a mutation at the COL1A2 locus. 5
1463018 1992
34
Estrogen status and heredity are major determinants of premenopausal bone mass. 57
1469098 1992
35
Genetic determinants of bone mass in adults. A twin study. 57
3624485 1987
36
Vertebroplasty combined with facet joint block vs. vertebroplasty alone in relieving acute pain of osteoporotic vertebral compression fracture: a randomized controlled clinical trial. 41
35999526 2022
37
The potential role of insulin-like growth factor 1, insulin-like growth factor binding protein 3 and bone mineral density in patients with chronic hepatitis C virus in Cairo, Egypt. 53 62
20189618 2010
38
The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. 53 62
20197302 2010
39
Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis. 53 62
20184423 2010
40
Osteocalcin gene polymorphisms influence concentration of serum osteocalcin and enhance fracture identification. 53 62
20200947 2010
41
Effect of glucocorticoid-, parathyroid- and thyroid hormones excess on human iliac crest bone matrix insulin-like growth factor (IGF)-I in patients with osteoporosis. 53 62
19998242 2010
42
Biochemical mechanism of gallium on prevention of fatal cage-layer osteoporosis. 53 62
19639269 2010
43
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. 53 62
19874198 2010
44
New treatment targets in osteoporosis. 53 62
20381400 2010
45
Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. 53 62
20116187 2010
46
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. 53 62
20079640 2010
47
Low density lipoprotein receptor-related protein 5 (LRP5) mutations and osteoporosis, impaired glucose metabolism and hypercholesterolaemia. 53 62
19673927 2010
48
The association of serum osteoprotegerin and osteoporosis in postmenopausal hemodialysis patients: a pilot study. 53 62
20210559 2010
49
Novel LRP5 gene mutation in a patient with osteoporosis-pseudoglioma syndrome. 53 62
20096619 2010
50
Genetics of osteoporosis: accelerating pace in gene identification and validation. 53 62
20101412 2010

Variations for Osteoporosis

ClinVar genetic disease variations for Osteoporosis:

5 (show all 42)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 COL1A2 NM_000089.4(COL1A2):c.1981G>A (p.Gly661Ser) SNV Pathogenic
17258 rs72658152 GRCh37: 7:94047820-94047820
GRCh38: 7:94418508-94418508
2 COL1A1 NM_000088.4(COL1A1):c.2089C>T (p.Arg697Ter) SNV Pathogenic
287320 rs72651642 GRCh37: 17:48269187-48269187
GRCh38: 17:50191826-50191826
3 COL1A1 NM_000088.4(COL1A1):c.1243C>T (p.Arg415Ter) SNV Pathogenic
425597 rs72648326 GRCh37: 17:48272649-48272649
GRCh38: 17:50195288-50195288
4 PLS3 NM_005032.7(PLS3):c.1512-1G>T SNV Pathogenic
1172590 GRCh37: X:114881869-114881869
GRCh38: X:115647549-115647549
5 COL1A1 NM_000088.4(COL1A1):c.1299+1G>A SNV Pathogenic
425599 rs66490707 GRCh37: 17:48272592-48272592
GRCh38: 17:50195231-50195231
6 COL1A1 NM_000088.4(COL1A1):c.1614+1G>A SNV Pathogenic
1074312 GRCh37: 17:48271709-48271709
GRCh38: 17:50194348-50194348
7 COL1A2 NM_000089.4(COL1A2):c.1531G>A (p.Gly511Ser) SNV Pathogenic
1694467 GRCh37: 7:94042422-94042422
GRCh38: 7:94413110-94413110
8 COL1A1 NM_000088.4(COL1A1):c.1821+1G>A SNV Pathogenic
425580 rs66555264 GRCh37: 17:48270354-48270354
GRCh38: 17:50192993-50192993
9 IFITM5 NM_001025295.3(IFITM5):c.-14C>T SNV Pathogenic
37143 rs587776916 GRCh37: 11:299504-299504
GRCh38: 11:299504-299504
10 COL1A1 NM_000088.4(COL1A1):c.2362G>A (p.Gly788Ser) SNV Pathogenic
447141 rs67879854 GRCh37: 17:48267939-48267939
GRCh38: 17:50190578-50190578
11 COL1A1 NM_000088.4(COL1A1):c.994G>A (p.Gly332Arg) SNV Pathogenic
17312 rs72645357 GRCh37: 17:48273524-48273524
GRCh38: 17:50196163-50196163
12 COL1A1 NM_000088.4(COL1A1):c.579del (p.Gly194fs) DEL Pathogenic
35925 rs72667023 GRCh37: 17:48275531-48275531
GRCh38: 17:50198170-50198170
13 COL1A2 NM_000089.4(COL1A2):c.982G>A (p.Gly328Ser) SNV Pathogenic
456848 rs66612022 GRCh37: 7:94039080-94039080
GRCh38: 7:94409768-94409768
14 COL1A2 NM_000089.4(COL1A2):c.1127G>T (p.Gly376Val) SNV Pathogenic
579070 rs67543427 GRCh37: 7:94039769-94039769
GRCh38: 7:94410457-94410457
15 COL1A2 NM_000089.4(COL1A2):c.3034G>A (p.Gly1012Ser) SNV Pathogenic
216908 rs72659319 GRCh37: 7:94055771-94055771
GRCh38: 7:94426459-94426459
16 COL1A1 NM_000088.4(COL1A1):c.3040C>T (p.Arg1014Cys) SNV Pathogenic
17347 rs72653170 GRCh37: 17:48266269-48266269
GRCh38: 17:50188908-50188908
17 COL1A2 NM_000089.4(COL1A2):c.577G>A (p.Gly193Ser) SNV Pathogenic
265387 rs72656370 GRCh37: 7:94035598-94035598
GRCh38: 7:94406286-94406286
18 COL1A2 NM_000089.4(COL1A2):c.432+2T>A SNV Likely Pathogenic
1675161 GRCh37: 7:94034206-94034206
GRCh38: 7:94404894-94404894
19 SRC NM_198291.3(SRC):c.1579G>A (p.Glu527Lys) SNV Likely Pathogenic
225689 rs879255268 GRCh37: 20:36031750-36031750
GRCh38: 20:37403347-37403347
20 LRP5 NM_002335.4(LRP5):c.2555C>T (p.Thr852Met) SNV Likely Pathogenic
1179140 GRCh37: 11:68181208-68181208
GRCh38: 11:68413740-68413740
21 LRP5 NM_002335.4(LRP5):c.3758G>A (p.Cys1253Tyr) SNV Likely Pathogenic
623483 rs768615287 GRCh37: 11:68197163-68197163
GRCh38: 11:68429695-68429695
22 COL1A1 NM_000088.4(COL1A1):c.985G>C (p.Gly329Arg) SNV Likely Pathogenic
450546 rs1555574303 GRCh37: 17:48273533-48273533
GRCh38: 17:50196172-50196172
23 OPA1-AS1, OPA1 NM_130837.3(OPA1):c.679-4G>T SNV Uncertain Significance
523555 rs757018661 GRCh37: 3:193343877-193343877
GRCh38: 3:193626088-193626088
24 SERPINF1 NM_002615.7(SERPINF1):c.336G>T (p.Leu112Phe) SNV Uncertain Significance
1342995 GRCh37: 17:1674375-1674375
GRCh38: 17:1771081-1771081
25 LRP5 NM_002335.4(LRP5):c.1199C>T (p.Ala400Val) SNV Uncertain Significance
520692 rs201320326 GRCh37: 11:68153967-68153967
GRCh38: 11:68386499-68386499
26 COL1A1 NM_000088.4(COL1A1):c.3994G>A (p.Asp1332Asn) SNV Uncertain Significance
578894 rs754984293 GRCh37: 17:48263689-48263689
GRCh38: 17:50186328-50186328
27 FBN1 NM_000138.5(FBN1):c.6170G>A (p.Arg2057Gln) SNV Uncertain Significance
1691560 GRCh37: 15:48730108-48730108
GRCh38: 15:48437911-48437911
28 LRP5 NM_002335.4(LRP5):c.4000+9C>T SNV Uncertain Significance
36481 rs148685646 GRCh37: 11:68201315-68201315
GRCh38: 11:68433847-68433847
29 LRP5 NM_002335.4(LRP5):c.3107G>A (p.Arg1036Gln) SNV Uncertain Significance
183255 rs61889560 GRCh37: 11:68191036-68191036
GRCh38: 11:68423568-68423568
30 COL1A1 NM_000088.4(COL1A1):c.3233T>C (p.Val1078Ala) SNV Uncertain Significance
324102 rs767525556 GRCh37: 17:48265485-48265485
GRCh38: 17:50188124-50188124
31 COL1A1 NM_000088.4(COL1A1):c.4196G>A (p.Arg1399His) SNV Uncertain Significance
450185 rs146035171 GRCh37: 17:48263191-48263191
GRCh38: 17:50185830-50185830
32 COL1A1 NM_000088.4(COL1A1):c.3169G>A (p.Val1057Ile) SNV Uncertain Significance
324103 rs575285203 GRCh37: 17:48265929-48265929
GRCh38: 17:50188568-50188568
33 COL1A1 NM_000088.4(COL1A1):c.1375C>A (p.Pro459Thr) SNV Uncertain Significance
388459 rs751299130 GRCh37: 17:48272168-48272168
GRCh38: 17:50194807-50194807
34 SERPINF1 NM_002615.7(SERPINF1):c.242C>G (p.Ser81Cys) SNV Uncertain Significance
218613 rs140512665 GRCh37: 17:1673303-1673303
GRCh38: 17:1770009-1770009
35 RYR1 NM_000540.3(RYR1):c.3202T>C (p.Cys1068Arg) SNV Uncertain Significance
373917 rs1057518768 GRCh37: 19:38958273-38958273
GRCh38: 19:38467633-38467633
36 COL1A2 NM_000089.4(COL1A2):c.52T>C (p.Cys18Arg) SNV Uncertain Significance
526891 rs200278401 GRCh37: 7:94024395-94024395
GRCh38: 7:94395083-94395083
37 COL1A2 NM_000089.4(COL1A2):c.286A>G (p.Met96Val) SNV Uncertain Significance
423747 rs763509640 GRCh37: 7:94033874-94033874
GRCh38: 7:94404562-94404562
38 COL1A2 NM_000089.4(COL1A2):c.671G>A (p.Arg224His) SNV Uncertain Significance
526896 rs771139732 GRCh37: 7:94037526-94037526
GRCh38: 7:94408214-94408214
39 COL1A2 NM_000089.4(COL1A2):c.3047C>A (p.Pro1016His) SNV Uncertain Significance
281098 rs377278762 GRCh37: 7:94055784-94055784
GRCh38: 7:94426472-94426472
40 COL1A2 NM_000089.4(COL1A2):c.3853A>C (p.Asn1285His) SNV Uncertain Significance
373178 rs144797861 GRCh37: 7:94058641-94058641
GRCh38: 7:94429329-94429329
41 COL1A2 NM_000089.4(COL1A2):c.2123G>A (p.Arg708Gln) SNV Uncertain Significance
17250 rs72658163 GRCh37: 7:94049588-94049588
GRCh38: 7:94420276-94420276
42 LRP5 NM_002335.4(LRP5):c.4635C>T (p.Thr1545=) SNV Likely Benign
36482 rs145406397 GRCh37: 11:68216325-68216325
GRCh38: 11:68448857-68448857

UniProtKB/Swiss-Prot genetic disease variations for Osteoporosis:

73
# Symbol AA change Variation ID SNP ID
1 WNT1 p.Cys218Gly VAR_069629 rs397514702
2 WNT1 p.Arg235Trp VAR_069630 rs387907359

Copy number variations for Osteoporosis from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 188155 4 59500000 76300000 Deletion UGT2B17 Osteoporosis
2 188566 4 66300000 70400000 Presence of gene UGT2B17 Osteoporosis
3 188584 4 66600000 70500000 Copy number TMPRSS11E Osteoporosis
4 188585 4 66600000 70500000 Copy number TMPRSS11E Osteoporosis
5 188586 4 66600000 70500000 Copy number UGT2B15 Osteoporosis
6 188587 4 66600000 70500000 Copy number UGT2B17 Osteoporosis
7 188588 4 66600000 70500000 Copy number YTHDC1 Osteoporosis

Expression for Osteoporosis

LifeMap Discovery
Genes differentially expressed in tissues of Osteoporosis patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 SCIMP SLP adaptor and CSK interacting membrane protein Blood + 4.32 0.000
2 LINC00189 long intergenic non-protein coding RNA 189 Blood + 3.93 0.000
3 ALAS2 5'-aminolevulinate synthase 2 Blood - 3.81 0.010
4 BTNL3 butyrophilin like 3 Blood - 3.78 0.042
5 LILRA5 leukocyte immunoglobulin like receptor A5 Blood + 3.25 0.017
6 HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 Blood + 3.17 0.006
7 SLC7A10 solute carrier family 7 member 10 Blood + 3.05 0.002
Search GEO for disease gene expression data for Osteoporosis.

Pathways for Osteoporosis

GO Terms for Osteoporosis

Cellular components related to Osteoporosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen type I trimer GO:0005584 8.92 COL1A2 COL1A1

Biological processes related to Osteoporosis according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 skeletal system development GO:0001501 10.08 TNFRSF11B COL1A2 COL1A1 BGLAP
2 response to mechanical stimulus GO:0009612 10.02 TNFRSF11A COL1A1 BGLAP
3 response to estrogen GO:0043627 10.01 TNFRSF11B ESR1 BGLAP
4 bone mineralization GO:0030282 10 IFITM5 COL1A2 BGLAP
5 monocyte chemotaxis GO:0002548 9.93 TNFSF11 TNFRSF11A CALCA
6 cellular response to zinc ion starvation GO:0034224 9.86 TNFRSF11A BGLAP
7 positive regulation of DNA-binding transcription factor activity GO:0051091 9.85 ESR1 LRP5 TNFRSF11A TNFSF11 WNT1
8 osteoclast differentiation GO:0030316 9.83 CALCR TNFRSF11A TNFSF11
9 tooth eruption GO:0044691 9.81 COL1A1 TNFSF11
10 mammary gland alveolus development GO:0060749 9.73 TNFSF11 TNFRSF11A ESR1
11 TNFSF11-mediated signaling pathway GO:0071847 9.71 TNFSF11 TNFRSF11A
12 amylin receptor signaling pathway GO:0097647 9.67 CALCR CALCA
13 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 9.67 TNFSF11 TNFRSF11A
14 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.62 TNFSF11 TNFRSF11A
15 bone development GO:0060348 9.56 WNT1 TNFSF11 PLS3 LRP5 BGLAP
16 ossification GO:0001503 9.32 TNFSF11 TNFRSF11A COL1A1 CALCR CALCA BGLAP

Molecular functions related to Osteoporosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet-derived growth factor binding GO:0048407 8.92 COL1A2 COL1A1

Sources for Osteoporosis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....